14 studies found for:    "Stargardt macular degeneration" [DISEASE] OR NCT00254605 [ID-NUMBER] OR NCT01278277 [ID-NUMBER] OR NCT00060749 [ID-NUMBER] OR NCT00346853 [ID-NUMBER] OR NCT00420602 [ID-NUMBER]
Show Display Options
Download search resultsDownload the search results for:
"Stargardt macular degeneration" [DISEASE] OR NCT00254605 [ID-NUMBER] OR NCT01278277 [ID-NUMBER] OR NCT00060749 [ID-NUMBER] OR NCT00346853 [ID-NUMBER] OR NCT00420602 [ID-NUMBER] (14 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Phase I/IIa Study of StarGen in Patients With Stargardt Macular Degeneration
Condition: Stargardt Disease
Intervention: Genetic: StarGen
2 Unknown  Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
Condition: Stargardt Disease
Intervention:
3 Unknown  DHA Supplementation in Patients With STGD3
Condition: Dominantly Inherited Stargardt's Disease (STGD3)
Intervention: Dietary Supplement: Over the counter DHA/EPA dietary supplementation
4 Enrolling by invitation A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen™ in Patients With Stargardt's Macular Degeneration
Condition: Stargardt Disease
Intervention: Drug: StarGen
5 Recruiting A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Condition: Stargardt Disease
Intervention:
6 Active, not recruiting Saffron Supplementation in Stargardt's Disease
Conditions: Retinal Degeneration;   Genetic Disease;   Single-Gene Defects;   Macular Dystrophy
Interventions: Dietary Supplement: Saffron supplementation;   Other: placebo
7 Completed Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-Like Macular Dystrophy
Condition: Macular Degeneration
Intervention: Drug: Docosahexaenoic Acid (DHA) Dietary Supplement
8 Recruiting Retinal Imaging in Patients With Inherited Retinal Degenerations
Condition: Retinitis Pigmentosa
Intervention:
9 Completed Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
Condition: Macular Dystrophy, Corneal
Interventions: Drug: 4-Methylpyrazole;   Other: saline
10 Active, not recruiting Phase 1 Safety Study of ALK-001 in Healthy Volunteers
Conditions: Stargardt Disease;   Age-related Macular Degeneration;   Other Retinal Dystrophies
Intervention: Drug: ALK-001 (No generic name)
11 Completed Microcurrent Stimulation to Treat Macular Degeneration
Conditions: Retinal Diseases;   Stargardt's Disease;   Retinitis Pigmentosa
Intervention:
12 Recruiting Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Conditions: Stargardt's Macular Dystrophy;   Fundus Flavimaculatus;   Juvenile Macular Dystrophy
Intervention: Biological: MA09-hRPE
13 Recruiting Stem Cell Ophthalmology Treatment Study
Conditions: Retinal Disease;   Macular Degeneration;   Hereditary Retinal Dystrophy;   Optic Nerve Disease;   Glaucoma
Interventions: Procedure: RB (Retrobulbar);   Procedure: ST (Subtenon);   Procedure: IV (Intravenous);   Procedure: IVIT (Intravitreal);   Procedure: IO (Intraocular)
14 Recruiting Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
Condition: Stargardt's Macular Dystrophy
Intervention: Biological: MA09-hRPE

Indicates status has not been verified in more than two years